Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_1
2
67%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 12 (66.7%)

Trials by Status

active_not_recruiting133%
recruiting133%
terminated133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingearly_phase_1

Early Intervention in High Risk CCUS

NCT06802146
active_not_recruitingphase_1

Inqovi Maintenance Therapy in Myeloid Neoplasms

NCT04980404
terminatedphase_1

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

NCT05918055

Clinical Trials (3)

Showing 3 of 3 trials
NCT06802146Early Phase 1

Early Intervention in High Risk CCUS

Recruiting
NCT04980404Phase 1

Inqovi Maintenance Therapy in Myeloid Neoplasms

Active Not Recruiting
NCT05918055Phase 1

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3